Cipla Targets $19 Billion-a-Year Roche, Amgen Drugs – BusinessWeek
By Dr. Matthew Watson
 Hindu Business Line | Cipla Targets $19 Billion-a-Year Roche, Amgen Drugs BusinessWeek Biotechnology drugs are made from proteins synthesized in living cells such as yeast and Chinese hamster ovaries. They are more complex, difficult to make ... China investment seals Cipla's biotech commitmentHindu Business Line Cipla to buy stake in two biotech cosDeccan Herald Cipla makes biotech foray with twin dealsCalcutta Telegraph Moneycontrol.com -Financial Express all 26 news articles » |
Uncategorized
Comments Off on Cipla Targets $19 Billion-a-Year Roche, Amgen Drugs – BusinessWeek |
June 16th, 2010
This author published 5472 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research